Transformation Journey | Avanos Medical embarks on a three-year plan to enhance efficiency and drive growth, with ambitious targets set for 2025 |
Financial Resilience | Q2 2024 results surpass expectations, with adjusted EPS of $0.34. Full-year guidance reaffirmed, projecting sales of $685-705 million |
Segment Performance | Digestive Health shines with 9% organic growth, while Pain Management faces challenges. Long-term strategy aims to balance portfolio |
Market Valuation | Trading at 13x 2025 EPS estimate of $1.80, Avanos' valuation reflects early-stage transformation and growth potential |
Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx’s knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Metrics to compare | AVNS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAVNSPeersSector | |
---|---|---|---|---|
P/E Ratio | 138.1x | −13.0x | −0.6x | |
PEG Ratio | 1.14 | −0.16 | 0.00 | |
Price/Book | 0.8x | 2.3x | 2.6x | |
Price / LTM Sales | 1.4x | 2.6x | 3.3x | |
Upside (Analyst Target) | 13.9% | 47.8% | 44.5% | |
Fair Value Upside | Unlock | 5.2% | 6.0% | Unlock |